Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
Intalight’s DREAM OCT Platform Cleared for EU Market with CE Mark
DREAM OCT scans from cornea to vitreous in one single scan, enabling full anterior segment imaging. Intalight (Shanghai, China), a…
latest posts
